New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 1, 2014
11:48 EDTBMYBristol-Myers recalls Coumadin for injection after particulate matter found
Bristol-Myers Squibb is voluntarily recalling six lots of Coumadin for injection, 5 mg single-use vials in the U.S. the FDA announced. This recall is a precautionary measure based on the company's investigation of visible particulate matter found in a small number of Coumadin for injection unreleased samples. Bristol-Myers Squibb believes the safety risk to patients is low, and is further mitigated by the product's prescribing information advising that intravenous drug products be inspected visually prior to administration. Coumadin for injection was discontinued in early April and the oral formulation, Coumadin tablets, is not impacted by this recall, the FDA noted.
News For BMY From The Last 14 Days
Check below for free stories on BMY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 17, 2014
07:43 EDTBMYBofA/Merrill to hold a conference
Subscribe for More Information
September 16, 2014
06:00 EDTBMYBristol-Myers announces Health Canada approval of Yervoy
Subscribe for More Information
September 5, 2014
16:45 EDTBMYMarket ends week little changed after mixed economic data
Subscribe for More Information
11:17 EDTBMYBristol-Myers files patent infringement suit against Merck
Subscribe for More Information
September 4, 2014
08:02 EDTBMYTeva launches generic Baraclude in U.S.
Teva (TEVA) announces the launch of the generic equivalent to Baraclude tablets in the U.S. Teva was first to file, making the product eligible for 180 days of marketing exclusivity. Baraclude is marketed by Bristol-Myers Squibb (BMY).

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use